Most Read Articles
Jackey Suen, 16 May 2014

Despite significant progress in liver disease control in recent years, China is still facing a lot of challenges which may be addressed with greater international cooperation.

01 Jun 2016
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
30 May 2016
Oral ombitasvir/paritaprevir/ritonavir and dasabuvir combination regimen is more cost-effective than standard treatment in patients with chronic genotype 1 hepatitis C virus (HCV) infection, as shown in a review.
03 Sep 2015
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.

AIT improves mortality, recurrence in HCC patients after curative treatment

02 Apr 2017

Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.

The Cochrane Library, Scopus, EMBASE and PubMed were searched for studies that investigated the effects of adjuvant AIT on HCC patients after curative treatments compared with either no interventions or control interventions. Those that considered advanced, unresectable or recurrent HCC were excluded.

The Newcastle-Ottawa and the Jadad scales were used to assess the quality of the non-randomized and observational trials, and randomized trials, respectively.

After applying the inclusion and exclusion criteria, eight studies (seven randomized controlled trials [RCT], one cohort study), corresponding to 949 treated and 912 untreated individuals, were included. Four of the RCTs had high methodological quality while three had low scores. The cohort study had a low risk of bias.

A fixed-effects model showed that, compared with curative therapies alone, adjuvant AIT was associated with improved mortality rates at 1 year (risk ratio [RR], 0.63; 95 percent CI, 0.50 to 0.78; p<0.001), 2 years (RR, 0.72; 0.63 to 0.83; p<0.001), 3 years (RR, 0.74; 0.65 to 0.83; p<0.001) and 5 years (RR, 0.88; 0.80 to 0.96; p=0.005).

Similarly, adjuvant AIT was associated with improvements in tumour recurrence rates at 1 year (RR, 0.80; 0.71 to 0.90; p=0.001), 2 years (RR, 0.80; 0.70 to 0.83; p<0.001), 3 years (RR, 0.86; 0.80 to 0.90; p<0.001) and 5 years (RR, 0.91; 0.85 to 0.97; p=0.004).

Finally, no serious adverse events or deaths were documented across the eight studies included. The most common adverse events were chills and fever. Tachycardia, itching, dizziness, myalgia, fatigue, nausea and headaches were also observed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 16 May 2014

Despite significant progress in liver disease control in recent years, China is still facing a lot of challenges which may be addressed with greater international cooperation.

01 Jun 2016
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
30 May 2016
Oral ombitasvir/paritaprevir/ritonavir and dasabuvir combination regimen is more cost-effective than standard treatment in patients with chronic genotype 1 hepatitis C virus (HCV) infection, as shown in a review.
03 Sep 2015
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.